Navigation Links
Bionovo Announces Third Quarter 2011 Highlights and Financial Results
Date:11/10/2011

tency compared to the highest dose tested in our Phase 2 study. This level of efficacy at 4 weeks is equivalent to or superior to estrogen-based hormone therapy.
  • The Company successfully completed non-clinical toxicology studies of Menerba in two animal species.  As expected, no serious adverse events or toxicities were observed to date from these studies, at doses much higher than are being tested in the Phase 3 clinical trial. The drug was well tolerated by the animals.
  • The Company has completed the manufacture of the requisite ten batches for the Phase 3 clinical trial of Menerba, and demonstrated to the FDA excellent consistency and quality.

  • Third Quarter ResultsTotal operating expenses for the three months ending September 30, 2011 were $6.4 million compared to $4.7 million for the same period in 2010. Total operating expenses for the third quarter included manufacturing costs at the Company's cGMP manufacturing facility in Hayward, California for ten clinical batches of Menerba, clinical trial costs for the tolerability trial assessing the safety and tolerability of higher doses of Menerba and other costs in preparation for the Company's Phase 3 trial of Menerba.

    The Company reported a net loss for the three months ended September 30, 2011 of $3.9 million, or $0.07 per share, compared with a net loss of $4.6 million, or $0.21 per share, for the same period in 2010.  The difference in net loss is primarily due to the increase in operating expenses as described above offset by the change in fair value of the Company's warrant liability representing a gain of $2.3 million included in non-operating income for the three months ended September 30, 2011.

    The Company ended the quarter with $8.1 million in cash, cash equivalents and short term investments, and began the quarter with $13.0 million, a difference of $4.9 million. The cash balance at the end of the quarter reflects the proceeds of the Company'
    '/>"/>

    SOURCE Bionovo, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Bionovo Initiates Menerba (MF101) Phase 3 Clinical Trial for Menopausal Hot Flashes
    2. Bionovo to Present Tissue Selective Estrogen Receptor Modulators for Obesity at the 22nd Annual Meeting of the North American Menopause Society
    3. Bionovo Announces an Additional 180 Day Period to Regain Compliance With Nasdaqs Bid Price Rule
    4. CORRECTED: Bionovo Announces Second Quarter 2011 Highlights and Financial Results
    5. Bionovo Announces Second Quarter 2011 Highlights and Financial Results
    6. Bionovo to Present the Clinical Promise of Menerba (MF101) for Postmenopausal Vasomotor Symptoms at World Congress on Menopause
    7. Bionovo to Announce First Quarter Financial Results on Wednesday, May 11, 2011
    8. Bionovo Announces Enrollment Started in the Menerba (MF101) Phase 1 "Tolerability" Clinical Trial for Menopausal Hot Flushes
    9. Bionovo Announces 2010 Highlights and Year-End Financial Results
    10. Bionovo, Inc. to Announce Fourth Quarter Fiscal Year 2010 Financial Results on Tuesday, March 15, 2011
    11. Bionovo to Present at the Cowen and Company 31st Annual Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/4/2015)... -- Eli Lilly and Company (NYSE: LLY ) ... comprehensive overview of the company,s corporate responsibility efforts. ... approach to corporate responsibility by increasingly leveraging its ... have greater, more sustainable impact. The ... thorough look at the company,s progress on numerous ...
    (Date:5/4/2015)... NASHVILLE, Tenn. , May 4, 2015  Verus ... after its acquisition of CPAP Care Club in 2012.  ... CPAP business within the durable medical equipment (DME) industry ... apnea patients for their CPAP supply needs and processes ... we bought this company three years ago, the systems ...
    (Date:5/4/2015)... , May 4, 2015 CytoSorbents ... company commercializing its CytoSorb® extracorporeal cytokine adsorber to ... countries worldwide, will report Q1 2015 financial results ... 2015.  CytoSorbents, management will host ... will recount both operational and financial progress during ...
    Breaking Medicine Technology:Lilly Releases Corporate Responsibility, Global Health Reports 2Lilly Releases Corporate Responsibility, Global Health Reports 3Lilly Releases Corporate Responsibility, Global Health Reports 4Verus Healthcare Celebrates 1,000% Growth on Third Anniversary 2CytoSorbents to Report Q1 2015 Operating and Financial Results 2CytoSorbents to Report Q1 2015 Operating and Financial Results 3
    ... for maintaining a healthy immune systemPURCHASE, N.Y., Jan. 6 ... Cancer (60(5), 643-651) by researchers at Kansai Medical ... Hexose Correlated Compound) enhances immune function by increasing the ... part of the immune system responsible for presenting foreign ...
    ... 6 Pacira Pharmaceuticals, Inc., an,acute care specialty ... in two pivotal Phase III SIMPLE trials to ... administration of EXPAREL(TM),(DepoBupivacaine) for prolonged postoperative analgesia. , ... in hemorrhoidectomy and in total knee,arthroplasty (TKA) are ...
    Cached Medicine Technology:Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells 2Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells 3Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment 2Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment 3
    (Date:5/4/2015)... The Lymphoma Research Foundation (LRF) – ... innovative lymphoma research and serving the lymphoma community through ... patient services – is set to host its annual ... West Orange, NJ on June 1, 2015. Since 2010, ... programs through LRF. , This year, the Lymphoma Research ...
    (Date:5/4/2015)... The opportunity for children to dream of ... motivating forces behind The Fairy Godmother Next Door, a new ... L. Stark. , The inspiration for the enchanting story of ... from Stark’s desire to be a fairy godmother. , “My ... to my neighbors’ children since they were born. We discuss ...
    (Date:5/4/2015)... 2015 In May of 2010, after two ... life. In the wake of this tragedy, Ty’s parents Kirk ... that exposes the grim reality of bullying and its devastating ... Kirk and Laura to share their story and offer education ... to another family — a mission that took the Smalley ...
    (Date:5/4/2015)... May 04, 2015 The U.S. healthcare ... boomers join the ranks of senior citizens (1) and ... an already over-burdened healthcare system. Additionally, as older healthcare ... replace them. Per the U.S. Census Bureau, the number ... increase 75% by 2050 while those 25 to 54 ...
    (Date:5/4/2015)... Ticket Down is a reputable source for ... . While the World Cup is the most known ... years, the International Champions Cup is one of the biggest ... attendance record for soccer in the United States set when ... the University of Michigan. This year, the defending champion Manchester ...
    Breaking Medicine News(10 mins):Health News:Lymphoma Research Foundation Set to Host Annual Ace Lymphoma Luncheon at Mayfair Farms in West Orange, NJ 2Health News:Introducing New Children’s Book The Fairy Godmother Next Door 2Health News:WWE Legend "Rowdy" Roddy Piper Teams Up with Stand for the Silent for Timely Anti-Bullying Campaign 2Health News:WWE Legend "Rowdy" Roddy Piper Teams Up with Stand for the Silent for Timely Anti-Bullying Campaign 3Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 2Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 3Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 4Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 2Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 3Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 4
    ... to Demonstrate Single-Agent Activity, - 38% Response Rate, 43% Disease Control ... Refractory Hodgkin Lymphoma ... in 110mg Cohort, ... Including an 18% Response Rate in Evaluable Diffuse Large B- cell ...
    ... that has saved more than 100,000 lives, now is saving ... disease progression with long term use in adults with chronic ... continues to show how much Gleevec has completely changed the ... Druker, M.D., director of the OHSU Cancer Institute. , ...
    ... ATLANTA, GA, December 8, 2007 -- Results from two ... with bortezomib provide preliminary anti-tumor activity in patients with ... study showed that 10 of 21 (48 percent) evaluable ... ZOLINZA and bortezomib combination treatment. Data from a ...
    ... 8, 2007 There is a clear link between GABA ... that inhibits neurons in the brain and ... the American College of Neuropsychopharmacology (ACNP) annual meeting. Researchers ... a finding which could potentially help curb the pleasurable ...
    ... Boca Raton, FL, December 8, 2007 Bipolar disorder, ... the circadian system the bodys internal clock ... irregularities in the circadian system that can trigger key ... today at the American College of Neuropsychopharmacology (ACNP) annual ...
    ... Dec. 7 On the heels of today,s,Human ... immigrant,detainees, AIDS Healthcare Foundation (AHF) today criticized the ... disregard for the,health and well-being of people living ... Indifference: HIV/AIDS Services for Immigrants,Detained by the U.S.," ...
    Cached Medicine News:Health News:Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting 2Health News:Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting 3Health News:Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting 4Health News:Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting 5Health News:Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting 6Health News:Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting 7Health News:Gleevec, the targeted cancer pill, delivers more good news to patients 2Health News:ZOLINZA (vorinostat) in combination with bortezomib demonstrated clinical activity 2Health News:ZOLINZA (vorinostat) in combination with bortezomib demonstrated clinical activity 3Health News:Study suggests nicotine addiction might be controlled by influencing brain mechanisms 2Health News:Studies find stable sleep patterns and regular routines may improve outcomes in bipolar disorder 2Health News:Studies find stable sleep patterns and regular routines may improve outcomes in bipolar disorder 3Health News:Denial of Care for HIV+ Detainees 'Unacceptable,' Says AHF 2
    ... Graham-Field has been developing ... than 58 years. Our medical-surgical ... reputation for innovation, quality and ... brands include the Labtron® line ...
    ... Vibrating Mesh Technology to efficiently deliver ... Asthma, COPD or other respiratory conditions. ... and handy carrying case that is ... Powerful delivery comparable to table-top compressor ...
    ... deliver particulate humidity in the 3 to ... patients. For your convenience, Thera-Mist® nebulizers may ... sterile water., ,The P30000N, for normal ... with a total flow range of 68-24 ...
    ... as well as humidification, try Flo-Mist™., ... volume, continuous medication nebulizer (CMN), engineered to ... 200 ml reservoir and jet flow design ... nebulized medication delivery at 25 ml/hr. Particles ...
    Medicine Products: